Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States
Yi‐Te Lee,Jasmine J. Wang,Michael Luu,Mazen Noureddin,Nicholas N. Nissen,Tushar C. Patel,Lewis R. Roberts,Amit G. Singal,Gregory J. Gores,Ju Dong Yang
DOI: https://doi.org/10.1002/hep.32007
IF: 17.298
2021-09-25
Hepatology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background & Aims</h3><p>Intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) are the most common primary liver cancers. Differences in their clinical features and outcomes have not been investigated in a large-scale study. We aim to investigate the differences in clinical features and outcomes between iCCA and HCC.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach & Results</h3><p>The Surveillance, Epidemiology, and End Results Program 18 Database (2000-2017) was used to extract demographic and clinical features of HCC and iCCA patients. Logistic regression analysis was performed to identify factors associated with iCCA diagnosis vs. HCC. Cox regression analysis was utilized to assess factors affecting overall survival (OS). There were 13,611 iCCA and 96,151 HCC patients. Half of iCCA (50.7%) and three-quarters of HCC (76.3%) patients were male. Diagnosis in recent year, age (<50 or ≥65), female sex, non-Hispanic white race, higher income, rural area, and higher tumor burden were independently associated with iCCA diagnosis vs. HCC. Patients with iCCA had worse OS than those with HCC (9 vs. 13 months, <i>P</i><0.001). However, OS was comparable between iCCA and HCC in multivariable analysis (adjusted hazard ratio [aHR]=1.02, 95% confidence interval [CI]=0.99-1.05). In subgroup analyses, iCCA was associated with better OS than HCC in patients with tumor ≥ 5 cm (aHR=0.83, 95% CI=0.80-0.86), lymph node involvement (aHR=0.76, 95% CI=0.72-0.81), distant metastasis (aHR=0.76, 95% CI=0.73-0.79), poorly/undifferentiated tumors (aHR=0.88, 95% CI=0.83-0.94), and those receiving non-curative treatment (aHR=0.96, 95% CI=0.93-0.98). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>We identified the demographic, socioeconomic, and clinical features associated with iCCA diagnosis over HCC among patients with primary liver cancer. Although iCCA patients presented at an advanced stage, OS was similar between iCCA and HCC in multivariable analysis. iCCA was associated with longer OS for subgroups with poor prognostic features.</p></section>
gastroenterology & hepatology